The abstract is read at the publisher; the summary is JClub's.
LLM-based extraction from 931 Ewing sarcoma diagnostic pathology reports over 19 years identifies Neuron-Specific Enolase (NSE) positivity as linked to worse overall survival, especially in non-metastatic disease.
- Why it matters: Risk stratification in Ewing sarcoma relies on clinical factors and may miss histologic heterogeneity, while pathology narratives are difficult to analyze at scale.
- What they did: Using an OpenAI o3 pipeline on OCR-processed, digitized pathology reports from six Children’s Oncology Group trials, the model extracted 17 IHC markers with 94% weighted accuracy and validated performance against human ground truth (n=200) and experts (n=48).
- The result: In Kaplan-Meier and multivariable Cox models adjusting for metastatic status, NSE positivity predicted inferior overall survival (HR 2.15, 95% CI 1.15–4.02, p=0.016), with the strongest association in non-metastatic patients (HR 5.64, p=0.0055), while S100 positivity was linked to improved survival (HR 0.58, 95% CI 0.34–1.00, p=0.046).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.